Saturday 22.10.2022

Scientific Session Satellite Symposium Main Program Seminar, Workshop
calendar export icon Export calendar
Session details 08:45–10:15
Seminar 1 (Parallel Sessions)

Living beyond Lymphoma

Room:Großer Saal (Gürzenich)
  • Patient perspective

  • Organisation of HL survivorship care in the UK, ADAPT program

  • Organisation of HL survivorship care in the Netherlands and design of INSIGHT costeffectiveness study

  • Organisation of HL survivorship care in the U.S.

Session details 08:45–10:15
Workshop 1 (Parallel Sessions)

The HL Microenvironment

Room:Kleiner Saal (Gürzenich)
  • Lessons from the Periphery – Single Cell Analyses of the Circulating Immune Signature in Hodgkin Lymphoma

  • Spatial Proteomic Analyses of the Intact Tumor Microenvironment in Hodgkin Lymphoma – One Cell or Region at a Time

  • Microenvironmental Lessons from the NIVAHL Trial

Session details 08:45–10:15
Workshop 2 (Parallel Sessions)

PET beyond Deauville

Room:Weinkeller (Gürzenich)
Session details 08:45–10:15
Workshop 3 (Parallel Sessions)

Innovation for Older Patients

Room:Marsilius Saal (Gürzenich)
  • Lymphoma Biology and Immunosenescence in Older Patients

  • Efficacy and Safety of Targeted Drugs in Older HL Patients

  • Current and Future Trial Landscape in Older Patients

  • Open Discussion Forum: Adressing Unmet Needs

Session details 08:45–10:15
(Parallel Sessions)

Joint EHA-ISHL Symposium

Room:Raatstube (Gürzenich)
Session details 10:30–12:00
Seminar 2 (Parallel Sessions)

Radiotherapy: Identifying the Beneficiaries

Room:Großer Saal (Gürzenich)
  • Indications and current policy for radiotherapy in early and advanced stage HL based on GHSG randomized studies

  • Who benefits from adding radiotherapy even if PET-negative based on the RAPID study data

  • The experience of incorporating RT into CAR-T cell salvage programs- Does it apply to HL patients?

Session details 10:30–12:00
Workshop 4 (Parallel Sessions)

Bringing Liquid Biopsy to Patients

Room:Kleiner Saal (Gürzenich)
  • Liquid Biopsy in Lymphoma: The Swiss / FIL? Experience

  • Liquid Biopsy in Lymphoma: The Cologne experience

  • Integrating Fragmentomics and MRD in Lymphoma

  • Challenges in bringing Liquid Biopsy to Lymphoma patients – Kick-off talk for round table

  • Challenges in bringing Liquid Biopsy to Lymphoma patients – Round table

Session details 10:30–12:00
Seminar 3 (Parallel Sessions)

Learning from Pediatric HL

Room:Marsilius Saal (Gürzenich)
  • Framing the discussion and key issues in adolescent and young adult Hodgkin Lymphoma

  • SEARCH for CAYAHL initiative

  • Importance of QoL and PROs in long-term follow-up of HL

  • Development and execution of S1826 trial: North American NCTN pediatric/adult collaboration

  • Lessons from European Network for Pediatric Hodgkin Lymphoma

Session details 10:30–12:00
Workshop 5 (Parallel Sessions)

NLPHL

Room:Weinkeller (Gürzenich)
Session details 10:30–12:00
Workshop 6 (Parallel Sessions)

Learning through International Collaboration

Room:Raatstube (Gürzenich)
Session details 12:15–13:45
Satellite Symposium

Opening paths to the next chapters of lymphoma treatmen

Room:Großer Saal (Gürzenich)
  • Welcome and Introduction to the topic

  • Hodgkin’s lymphoma as a model for immuno-oncologic therapeutic approaches to lymphoma

  • The challenge of the older patient in lymphoma therapy

  • New trends in lymphoma therapy: future role of BTKi / CAR-T / bispecific antibodies

  • Summary and farewell

Session details 14:00–15:30
Scientific Session 1

Early Stages

Room:Großer Saal (Gürzenich)
Session details 16:00–17:30
Satellite Symposium

CAR T cell therapy in B Cell NHL: Status quo and future perspectives

Room:Großer Saal (Gürzenich)
  • Status quo of CAR T cell therapy for r/r DLBCL

  • New perspective for the treatment of r/r CLL

  • CAR T – Lessons Learned

Session details 18:00–19:00
Main Program

Opening and Award Ceremony

Room:Großer Saal (Gürzenich)
Session details 19:00–20:30
Main Program

Poster Session

Room:Foyer (Ground Floor) (Gürzenich)
Session details 19:00
Main Program

Welcome Reception

Room:Foyer (First Floor) (Gürzenich)

Sunday 23.10.2022

Scientific Session Satellite Symposium Main Program Seminar, Workshop
calendar export icon Export calendar
Session details 07:30–09:00
Scientific Session 2

Interactive Case Discussion

Room:Großer Saal (Gürzenich)
Session details 09:15–10:15
Scientific Session 3

Emerging Cellular Therapies – a Role in HL?

Room:Großer Saal (Gürzenich)
Session details 10:30–12:00
Scientific Session 4

Living beyond Lymphoma

Room:Großer Saal (Gürzenich)
Session details 12:15–13:45
Satellite Symposium

Checkpoint Inhibition in Hodgkin Lymphoma – State of the art and future perspectives

Room:Großer Saal (Gürzenich)
  • Firstline therapy of classical Hodgkin Lymphoma – How can immunotherapy improve outcome?

  • The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin Lymphoma

  • Strategies to enhance checkpoint inhibition

Session details 14:00–15:30
Scientific Session 5

Older and Frail Patients

Room:Großer Saal (Gürzenich)
Session details 16:00–17:30
Satellite Symposium

Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory Hodgkin Lymphoma

Room:Großer Saal (Gürzenich)
Session details 18:00–19:30
Scientific Session 6

Immunotherapy

Room:Großer Saal (Gürzenich)
  • New findings and new challenges since last ISHL

  • Vision Corner: The future of translational science in Hodgkin

  • Vision Corner: Best use of PD1 blockade in front-line

  • Vision Corner: Leveraging PD1 blockade for cure

  • abstract talk Abstract Talk: T057 Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume

  • abstract talk Abstract Talk: P061 Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Monday 24.10.2022

Scientific Session Satellite Symposium Main Program Seminar, Workshop
calendar export icon Export calendar
Session details 07:30–09:00
Scientific Session 7

Advanced Stages

Room:Großer Saal (Gürzenich)
Session details 09:15–10:15
Scientific Session 8

Special Situations in HL

Room:Großer Saal (Gürzenich)
Session details 10:30–12:00
Scientific Session 9

Genomics, Biology and Microenvironment

Room:Großer Saal (Gürzenich)
Session details 12:15–13:45
Satellite Symposium

Bridging the gap between efficacy and toxicity in the treatment of stage IV Hodgkin lymphoma

Room:Großer Saal (Gürzenich)
  • Hot Off the Press: The Latest Data for ECHELON-1

  • Case Study #1 Female, early-30s

  • Case Study #2 Male, late-70s

  • Case Study #3 Male, mid-50s

  • Q&A

Session details 14:00–15:30
Scientific Session 10

Relapsed / Refractory HL

Room:Großer Saal (Gürzenich)
Session details 15:30–16:00
Main Program

Closing Remarks

Room:Großer Saal (Gürzenich)
Session details 16:00–17:30
Main Program

Farewell

Room:Großer Saal (Gürzenich)

Gürzenich: Ground Floor

Allocations

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of Gürzenich: Ground Floor Go to Basement Go to Basement Go to First Floor Go to First Floor Kleiner Saal Marsilius Saal Foyer (Ground Floor) Gürzenich: Ground Floor

Gürzenich: Basement

Allocations

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of Gürzenich: Basement Go to Ground Floor Go to Ground Floor Weinkeller Raatstube Gürzenich: Basement

Gürzenich: First Floor

Allocations

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of Gürzenich: First Floor Go to Ground Floor Go to Ground Floor Großer Saal Isabellensaal Foyer (First Floor) Gürzenich: First Floor

Exhibition

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Map of the exhibition. Map of the Gürzenich: First Floor showing the location of 0 exhibitors. Stair to Ground Floor Stair to Ground Floor Großer Saal Isabellensaal Foyer (First Floor)

Early Stages

Selected for Oral Presentation

  • Show Details

    T020 (136) Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies

    • Dennis A. Eichenauer
    • Ina Bühnen
    • Michael Fuchs
    • Richard Greil
    • Alden Moccia
    • Josée M. Zijlstra
    • Sylvia Hartmann
    • Carsten Kobe
    • Markus Dietlein
    • Andreas Engert
    • Peter Borchmann
  • Show Details

    T021 (124) Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.

    • Andrea Gallamini
    • Marco Picardi
    • Kateryna Filonenko
    • Manuel Gotti
    • Javier Núñez Céspedes
    • Andrea Rossi
    • Eva Domingo-Domènech
    • Agnieszka Giza
    • Roberto Sorasio
    • Livio Trentin
    • Mariana Bastos Oteiro
    • Ewa Paszkiewicz-Kozik
    • Ramon García Sanz
    • Caterina Patti
    • Stephane Chauvie
    • Fabrizio Bergesio
    • Luca Guerra
    • Alessandro Rambaldi
    • Ana Sureda Balari
    • Jan Maciej Zaucha
  • Show Details

    T022 (63) Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK

    • Rebecca Shakir
    • Catriona Gilmour-Hamilton
    • Craig Bakin
    • Isabelle Gent
    • Adam Holloway
    • Alison Meeson
    • Johanna Ramroth
    • Georgios Ntentas
    • David Cutter
    • Michele Peters

Posters

  • Show Details

    P023 (104) PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma

    • Heidi Mocikova
    • Jana Markova
    • Lubica Gaherova
    • Maria Maco
    • Alice Sýkorová
    • David Belada
    • Marie Lukášová
    • Vit Prochazka
    • Juraj Duras
    • Tomas Kozak
  • Show Details

    P024 (142) Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial

    • Lutz van Heek
    • Colin Stuka
    • Helen Kaul
    • Horst Müller
    • Jasmin Mettler
    • Felicitas Hitz
    • Christian Baues
    • Michael Fuchs
    • Peter Borchmann
    • Andreas Engert
    • Markus Dietlein
    • Conrad-Amadeus Voltin
    • Carsten Kobe
  • Show Details

    P025 (150) RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma.

    • John Radford
    • Toyin Adedayo
    • Arzhang Ardavan
    • Sally F. Barrington
    • Leanne Berkahn
    • Stephane Chauvie
    • Laura Clifton-Hadley
    • Graham P. Collins
    • Michael Crump
    • David Cutter
    • Darren Edwards
    • Martin Hutchings
    • Tim Illidge
    • Amy A. Kirkwood
    • Kim Linton
    • Craig H. Moskowitz
    • Pip Patrick
    • Beth Phillips
    • Lois Shepherd
    • Sanne Tonino
    • Judith Trotman
    • Joanna Williams
    • Nicole Wong Doo

Living beyond Lymphoma

Selected for Oral Presentation

  • Show Details

    T064 (169) Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors

    • Suzanne I.M. Neppelenbroek
    • Yvonne M.G. Geurts
    • Berthe M. P. Aleman
    • Cécile P.M. Janus
    • Pieternella J. Lugtenburg
    • Saskia E. Rademaker
    • Roel J. de Weijer
    • Maaike G.A. Schippers
    • Bastiaan D.P. Ta
    • Wouter J. Plattel
    • Josée M. Zijlstra
    • Richard W.M. van der Maazen
    • Marten R. Nijziel
    • Francisca Ong
    • Erik C. Schimmel
    • Eduardus F.M. Posthuma
    • Marie José Kersten
    • Lara H. Böhmer
    • Karin Muller
    • Harry R. Koene
    • Liane C.J. te Boome
    • Yavuz M. Bilgin
    • Eva de Jongh
    • Flora E. van Leeuwen
    • Michael Schaapveld
  • Show Details

    T065 (58) Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway

    • Joshua P. Entrop
    • Caroline E. Weibull
    • Karin E. Smedby
    • Lasse Hjort Jakobsen
    • Andreas K. Øvlisen
    • Daniel Molin
    • Ingrid Glimelius
    • Anna Marklund
    • Harald Holte
    • Alexander Fosså
    • Knut B. Smeland
    • Tarec Christoffer El-Galaly
    • Sandra Eloranta
  • Show Details

    T066 (182) Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study.

    • Michaela Dinan
    • Kayla Stratton
    • Wendy Leisenring
    • Yutaka Yasui
    • Eric Chow
    • Emily Tonorezos
    • Chaya Moskowitz
    • Jennifer Yeh
    • David Noyd
    • Gregory Armstrong
    • Kevin Oeffinger

Posters

  • Show Details

    P067 (133) A pilot of lung cancer screening for survivors of Hodgkin lymphoma

    • Rachel Broadbent
    • Philip Crosbie
    • John Radford
    • Christopher J. Armitage
    • Ben Taylor
    • Joseph Mercer
    • Sean Tenant
    • Kim Linton
  • Show Details

    P068 (157) A Retrospective Analysis of Fertility in Female Patients with Advanced Stages of Hodgkin Lymphoma Treated with BEACOPP Escalated Chemotherapy (25 Year Experience of a Single Centre)

    • Jana Marková
    • Heidi Mociková
    • Lubica Gaherová
    • Katerina Klásková
    • Maria Maco
    • Katerina Dedeckova
    • Tomas Kozak
  • Show Details

    P069 (95) Characterisation of influencing parameters on oocyte quality preservation in a cohort of Hodgkin lymphoma patients

    • Chloé Chuzel
    • Virginie Simon
    • Hélène Béhal
    • Franck Morschhauser
    • Christine Decanter
    • Morgane Nudel
  • Show Details

    P070 (81) Design of the INSIGHT study, evaluation of long-term follow-up care for lymphoma survivors in the Netherlands: does survivorship care at the BETER clinics reduce morbidity and mortality from late effects of lymphoma treatment and associated costs?

    • Annelies Nijdam
    • Eline M.J. Lammers
    • Berthe M. P. Aleman
    • Josée M. Zijlstra
    • Flora E. van Leeuwen
    • on behalf of the BETER consortium
  • Show Details

    P071 (100) First results of cardiovascular screening in a survivorship care program for Hodgkin lymphoma survivors in the Netherlands

    • Eline M.J. Lammers
    • Annelies Nijdam
    • Josée M. Zijlstra
    • Cécile P.M. Janus
    • Roel J. de Weijer
    • Flora E. van Leeuwen
    • Berthe M. P. Aleman
    • on behalf of the BETER consortium
  • Show Details

    P072 (130) Impact of Ageing on the Survivorship Experiences of Patients with Hodgkin Lymphoma

    • Cherie Bates
    • Funmi Bamigbola
    • Lorna Warwick
  • Show Details

    P073 (107) Increased risk of colorectal cancer following treatment for Hodgkin lymphoma

    • Yvonne M.G. Geurts
    • Rebecca Shakir
    • Georgios Ntentas
    • Sander Roberti
    • Marianne Aznar
    • Katinka John
    • Johanna Ramroth
    • Cécile P.M. Janus
    • Augustinus Krol
    • Judith Roesink
    • Richard W.M. van der Maazen
    • Josée M. Zijlstra
    • Sarah Darby
    • Berthe M. P. Aleman
    • Flora E. van Leeuwen
    • David Cutter
    • Michael Schaapveld
  • Show Details

    P074 (72) Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients – A Nationwide Danish Cohort Study

    • Sára Rossetti
    • Sidsel Jacobsen Juul
    • Frank Eriksson
    • Peder Emil Warming
    • Charlotte Glinge
    • Tarec Christoffer El-Galaly
    • Jacob Haaber Christensen
    • Peter Kamper
    • Peter de Nully Brown
    • Maja Vestmø Maraldo
    • Jacob Tfelt-Hansen
    • Martin Hutchings
  • Show Details

    P075 (160) My Hodgkin, My Health: Feasibility of a mobile application to collect long term follow up data about Hodgkin patients.

    • Gajan Kailainathan
    • Janlyn Falconer
    • Amy Baker
    • Nicole Wong Doo
    • Judith Trotman
  • Show Details

    P076 (98) Pneumococcal infection in splenectomised Hodgkin lymphoma patients: Do they pose a problem today and what is the best long-term strategy?

    • Magnus Björkholm
    • Caroline E. Weibull
    • Paul Dickman
  • Show Details

    P077 (108) Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin lymphoma patients, using pre-chemotherapy PET-CT scans

    • Rebecca Shakir
    • Victoria Butterworth
    • Georgios Ntentas
    • Johanna Ramroth
    • David Cutter
  • Show Details

    P078 (106) Predicting the Health-Related Quality of Life of Hodgkin Lymphoma Survivors: Identification of Risk Factors

    • Nele Stadtbaeumer
    • Axel Mayer
    • Peter Borchmann
  • Show Details

    P079 (109) PROCTCAE as a patient-reported outcome measurement (PROM) questionaire in patients with Hodgkin Lymphoma captures different adverse events profile than those reported by physicians

    • Sergio Ramos-Cillan
    • Eva Castillo
    • Miriam Riesco
    • Antonio Herroro
    • Adriana Pascual
    • Alberto Lopez-Garcia
    • Maria Angeles Perez
    • Daniel Morillo
    • ALham Askari
    • Elena Prieto
    • Pilar LLamas
    • Javier Becares
    • Carla Barriocanal
    • Marta Del Olmo
    • Jorge Short
    • Javier Arcos
    • Raul Córdoba
  • Show Details

    P080 (64) The BETER-REFLECT Biobank: a REsource For studies on Late Effects of Cancer Treatment

    • Adinda Mieras
    • Annelies Nijdam
    • Berthe M. P. Aleman
    • Laurien Daniels
    • Eva de Jongh
    • Cécile P.M. Janus
    • Stijn Krol
    • Bastiaan D.P. Ta
    • Francisca Ong
    • Dick Johan van Spronsen
    • Ward Posthuma
    • Wouter J. Plattel
    • Rimke Oostvogels
    • Karijn Verschueren
    • Josée M. Zijlstra
    • Flora E. van Leeuwen
  • Show Details

    P081 (118) Treatment-related circulatory diseases and mortality in Hodgkin lymphoma patients using multi-state modelling and relative survival

    • Joachim Baech
    • Lasse Hjort Jakobsen
    • Tarec Christoffer El-Galaly
    • Daniel Molin
    • Ingrid Glimelius
    • Joshua P. Entrop
    • Michael J. Crowther
    • Karin E. Smedby
    • Sandra Eloranta
    • Caroline E. Weibull

Older & Frail Patients

Selected for Oral Presentation

  • Show Details

    T082 (147) AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients.

    • Ninja Övergaard
    • Kjersti Lia
    • Peter Asdahl
    • Per Wikman
    • Ingrid Glimelius
    • Ingemar Lagerlöf
    • Ann-Sofie Johansson
    • Lotta Hansson
    • Gunilla Enblad
    • Johan Linderoth
    • Christina Goldkuhl
    • Alexander Fosså
    • Peter Kamper
    • Daniel Molin
  • Show Details

    T083 (127) The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma

    • Jenica Upshaw
    • Jason Nelson
    • Angie Mae Rodday
    • Anita Kumar
    • Andreas Klein
    • Marvin Konstam
    • John Wong
    • Iris Jaffe
    • Bonnie Ky
    • Jonathan W. Friedberg
    • Matthew Mauer
    • David Kent
    • Susan K. Parsons
  • Show Details

    T084 (71) Treatment patterns and outcomes for Hodgkin's Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry

    • Lilian Goveia
    • Nelson Castro
    • Carmino de Souza
    • Carolina Colaço Villarim
    • Fabiola Traina
    • Carlos Sergio Chiattone
    • Monica Praxedes
    • Cristiana Solza
    • Leila Perobelli
    • Otavio Baiocchi
    • Rafael Gaiolla
    • Carla Boquimpani
    • Valeria Buccheri
    • Caroline Bonamin Sola
    • Roberta Oliveira de Paula e Silva
    • Ana Carolina Ribas
    • Giovana Steffenello
    • Katia Pagnano
    • Andrea Soares
    • Samuel Souza Medina
    • Talita Silveira
    • Karin Zattar Cecyn
    • Leonardo Carvalho Palma
    • Mariana de Oliveira Marques
    • Nelson Spector
    • Irene Biasoli

Posters

  • Show Details

    P085 (184) Epidemiology and results of the first line therapy of HIV-related Hodgkin Lymphoma: Russian retrospective multicenter study

    • Andrey Chekalov
    • Marina Popova
    • Ivan Tsygankov
    • Yuliya Rogacheva
    • Nikita Volkov
    • Anastasia Beynarovich
    • Kirill Lepik
    • Marina Demchenkova
    • Marina Grigorieva
    • Tatiana Schneider
    • Yuliya Kopeikina
    • Natalia Medvedeva
    • Ilya Zyuzgin
    • Elena Pavlyuchenko
    • Alexander Levanov
    • Alexander Myasnikov
    • Natalia Mikhailova
    • Vadim Baykov
    • Alexander Kulagin

Immunotherapy

Selected for Oral Presentation

  • Show Details

    T057 (59) Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume

    • Ryan C. Lynch
    • Stefan Alig
    • Chaitra S. Ujjani
    • Christina Poh
    • Edus H. Warren
    • Stephen D. Smith
    • Mazyar Shadman
    • Andrei Shustov
    • Brian Till
    • Vikram M. Raghunathan
    • Yolanda Tseng
    • Hilary Coye
    • Megan Shelby
    • Susan Ottemiller
    • Sarith Keo
    • Kaitlin Verni
    • Hongyan Du
    • Jackie Vandermeer
    • Ashley Gaston
    • Heather Rasmussen
    • Avanti Gulhane
    • Delphine L. Chen
    • Paul Martin
    • Edmond Marzbani
    • Jenna Voutsinas
    • Ash A. Alizadeh
    • Ajay K. Gopal
  • Show Details

    P061 (174) Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

    • Peter Borchmann
    • Nathalie A. Johnson
    • David Lavie
    • Gareth Gregory
    • Alex F. Herrera
    • Leonard Minuk
    • Vladan Vucinic
    • Philippe Armand
    • Abraham Avigdor
    • Robin Gasiorowski
    • Yair Herishanu
    • Colm Keane
    • John Kuruvilla
    • John Palcza
    • Pallavi Pillai
    • Akash Nahar
    • John Timmerman

Posters

  • Show Details

    P059 (129) Multi-effector cell targeting with half-life extended bispecific scFv in Hodgkin lymphoma

    • Zhiyuan Shi
    • Verena Kern
    • Max Freihammer
    • Jennifer Schitz
    • Sven Borchmann
  • Show Details

    P060 (167) Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment

    • Liudmila Fedorova
    • Kirill Lepik
    • Natalia Mikhailova
    • Elena Kondakova
    • Yaroslava Komarova
    • Polina Kotselyabina
    • Evgenia Borzenkova
    • Vadim Baykov
    • Ivan Moiseev
    • Alexander Kulagin
  • Show Details

    P062 (166) The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma

    • Liudmila Fedorova
    • Kirill Lepik
    • Natalia Mikhailova
    • Elena Kondakova
    • Yaroslava Komarova
    • Polina Kotselyabina
    • Evgenia Borzenkova
    • Vadim Baykov
    • Ivan Moiseev
    • Alexander Kulagin
  • Show Details

    P063 (189) Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial

    • Paul J. Bröckelmann
    • Helen Kaul
    • Michael Fuchs
    • Carsten Kobe
    • Christian Baues
    • Peter Borchmann
    • Andreas Engert
  • Show Details

    T058 (179) Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment

    • John Timmerman
    • David Lavie
    • Nathalie A. Johnson
    • Abraham Avigdor
    • Peter Borchmann
    • Charalambos Andreadis
    • Ali Bazargan
    • Gareth Gregory
    • Colm Keane
    • Inna Tzoran
    • Vladan Vucinic
    • Pier Luigi Zinzani
    • Hong Zhang
    • Pallavi Pillai
    • Akash Nahar
    • Alex F. Herrera

Advanced Stages

Selected for Oral Presentation

  • Show Details

    T001 (134) FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial

    • Arjan Diepstra
    • Lydia Visser
    • Catherine Fortpied
    • Walter Noordzij
    • Annika Loft
    • Anne Arens
    • Anna Sureda-Balari
    • Susana Carvalho
    • Andrej Vranovský
    • Ward Sents
    • Emanuel Buhrer
    • Wouter J. Plattel
    • Martin Hutchings
  • Show Details

    T002 (193) Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

    • Peter Borchmann
    • Alden Moccia
    • Richard Greil
    • Mark Herzberg
    • Alexander Fosså
    • Andreas Hüttmann
    • Felix Keil
    • Judith Dierlamm
    • Valdete Schaub
    • Mathias Hänel
    • Urban Novak
    • Julia Meissner
    • Johannes Hellmuth
    • Stephan Mathas
    • Josée M. Zijlstra
    • Andreas Viardot
    • Bernd Hertenstein
    • Sonja Martin
    • Pratush Giri
    • Stefanie Kreissl
    • Michael Fuchs
    • Gundolf Schneider
    • Andreas Rosenwald
    • Wolfram Klapper
    • Hans Theodor Eich
    • Christian Baues
    • Michael Hallek
    • Carsten Kobe
    • Volker Diehl
    • Andreas Engert

Posters

  • Show Details

    P003 (92) A retrospective study to evaluate the reliability of staging and risk stratification of adolescent and adult patients with Hodgkin’s lymphoma registered in the lymphoma clinic at Tata Memorial Centre.

    • Hasmukh Jain
    • Ajay Singh
    • Manju Sengar
    • Thomas Eipe
    • Hiral Mehta
    • Bhausaheb Bagal
    • Jayashree Thorat
    • Lingaraj Nayak
    • Neha Sharma
  • Show Details

    P004 (80) Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials

    • Simonetta Viviani
    • Chiara Pavoni
    • Sally F. Barrington
    • Luca Guerra
    • Heiko Schöder
    • Peter Johnson
    • Amy A. Kirkwood
    • Deborah M. Stephens
    • Jonathan W. Friedberg
    • Stephane Chauvie
    • Michael V. Knopp
    • Massimo Federico
    • Gunilla Enblad
    • Paolo Corradini
    • Andrea Gallamini
    • Alessandro Rambaldi
    • Corrado Tarella
  • Show Details

    P005 (66) Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin lymphoma, even the PET-adapted era. A single center retrospective study.

    • Andrea Visentin
    • Alessandro Cellini
    • Chiara Adele Cavarretta
    • Leila Romano Gargarella
    • Francesco Angotzi
    • Valeria Ruocco
    • Simone Zoletto
    • Stefano Pravato
    • Marco Pizzi
    • Federica Vianello
    • Filippo Crimì
    • Stefania Vio
    • Michele Gregianin
    • Livio Trentin
  • Show Details

    P006 (135) Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi

    • Chiara Rusconi
    • Benedetta Puccini
    • Carlo Visco
    • Francesca Ricci
    • Alessandro Re
    • Vittorio R. Zilioli
    • Caterina Zerbi
    • Stefan Hohaus
    • Federico Mazzon
    • Manuel Ciceri
    • Anna Guidetti
    • Vincenzo Marasco
    • Luigi Rigacci
  • Show Details

    P007 (178) Comparative efficacy of the R-BEACOPP-14 and R-CHOP regimens in the treatment of patients with advanced stages of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with THRLBCL-like histopathological growth patterns in the tumor biopsy

    • Elena Dorokhina
    • T.N. Moiseeva
    • A.M. Kovrigina
    • Irirna Shupletsova
    • L.S. Al-Radi
    • Yu. A. Chabaeva
    • Ya.K. Mangasarova
  • Show Details

    P008 (57) Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma

    • Conrad-Amadeus Voltin
    • Stefanie Kreissl
    • Helen Kaul
    • Ina Bühnen
    • Jasmin Mettler
    • Thomas Pabst
    • Dennis A. Eichenauer
    • Michael Fuchs
    • Volker Diehl
    • Markus Dietlein
    • Andreas Engert
    • Peter Borchmann
    • Carsten Kobe
  • Show Details

    P009 (99) Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1

    • Martin Hutchings
    • Stephen M. Ansell
    • Joseph M. Connors
    • Won Seog Kim
    • Andrea Gallamini
    • Radhakrishnan Ramchandren
    • Jonathan W. Friedberg
    • Ranjana Advani
    • Andrew M. Evens
    • Piotr Smolewski
    • Kerry J. Savage
    • Nancy L. Bartlett
    • Hyeon-Seok Eom
    • Jeremy S. Abramson
    • Cassie Dong
    • Frank Campana
    • Keenan Fenton
    • Markus Puhlmann
    • David J. Straus
    • John Radford
  • Show Details

    P010 (121) Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium

    • Susan K. Parsons
    • Angie Mae Rodday
    • Jonathan W. Friedberg
    • Andrea Gallamini
    • Eliza Hawkes
    • David Hodgson
    • Peter Johnson
    • Brian Link
    • Matthew Maurer
    • Jason Nelson
    • Kerry J. Savage
    • Jenica Upshaw
    • Pier Luigi Zinzani
    • Andrew M. Evens
  • Show Details

    P011 (188) IPS-7 or IPS-3 to identify very-high risk patients in advanced Classical Hodgkin ́s Lymphoma: Which score to choose

    • Cátia Almeida
    • Rita Costa e Sousa
    • Adriana Roque
    • Maria Carolina Afonso
    • Dulcelena Neves
    • Raquel Guilherme
    • Lenka Ruzickova
    • José Pedro Carda
    • Catarina Geraldes
    • Marília Gomes
  • Show Details

    P012 (131) Nodular Lymphocyte-predominant Hodgkin Lymphoma a rare disease with good prognosis: a retrospective multicenter experience

    • Francesca Pierdomenico
    • Raquel Marques
    • Dulcelena Neves
    • João Gaião Santos
    • Christopher Saunders
    • Rita Pinho Peixeiro
    • Marta Henriques
    • Ana Tome
    • Daniela Alves
    • Margarida Badior
    • Tathiane Lopes
    • Sonia Leocadio
    • Marília Gomes
    • Alexandra Monteiro
    • Rita Coutinho
    • Ana Luisa Pinto
    • Anabela Neves
    • João Paulo Fernandes
    • Maria Gomes da Silva
  • Show Details

    P013 (103) Outcomes of first-line treatment (FL) of classical Hodgkin lymphoma (cHL) in Argentina: a real life multicenter retrospective study

    • Korin Laura
    • Victoria Otero
    • Carolina Mahuad
    • Enriqueta Martinez
    • Fernando Warley
    • Hernan García Rivello
    • Nancy Cristaldo
    • Dana Kohan
    • Gonzalo Garate
    • Maria de los Angeles Vicente Reparaz
    • Maria Florencia Aizpurua
    • Erica Rojas Bilbao
    • Susana Cerana
    • María Eugenia Funes
    • Iliana Plaza
    • Cecilia Foncuberta
    • Anahi Vijnovich Baron
    • Santiago Cranco
    • Adriana Vitriu
    • Mariela Gomez
    • Justina Lavalle
    • Claudia Casali
    • Manuela Clavijo
    • Luciana Melillo
    • Maria Cecilia Cabral Lorenzo
    • Augusto Miroli
    • Laura Fishman
    • Maximi
  • Show Details

    P014 (186) Prognostic significance of nutritional indexes (CONUT and PNI) in classical Hodgkin lymphoma patients

    • Rita Costa e Sousa
    • Cátia Almeida
    • Adriana Roque
    • Maria Carolina Afonso
    • Dulcelena Neves
    • Raquel Guilherme
    • Lenka Ruzickova
    • José Pedro Carda
    • Catarina Geraldes
    • Marília Gomes
  • Show Details

    P015 (94) Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity

    • Anna Santarsieri
    • Katherine Sturgess
    • Pauline Brice
    • Tobias F. Menne
    • Wendy Osborne
    • Thomas Creasey
    • Kirit M. Ardeshna
    • Sarah Behan
    • Kaljit Bhuller
    • Stephen Booth
    • Nikesh Chavda
    • Graham P. Collins
    • Dominic Culligan
    • Kate Cwynarski
    • Andrew Davies
    • David Dutton
    • Michelle Furtado
    • Eve Gallop-Evans
    • Andrew Hodson
    • David Hopkins
    • Hannah Hsu
    • Sunil Iyengar
    • Stephen G. Jones
    • Kim Linton
    • Oliver Lomas
    • Nicolas Martinez-Calle
    • Abhinav Mathur
    • Pamela McKay
    • Sateesh K. Nagumantry
    • Deidre O'Mahony
    • Beth Phillips
    • Neil
  • Show Details

    P016 (152) Reduced steroid exposure is safe and does not reduce disease control among Hodgkin Lymphoma patients treated with escalated BEACOPP (eBEACOPP)

    • Ida Hude Dragičević
    • Sandra Bašić-Kinda
    • Dino Dujmović
    • Ivo Radman
    • Barbara Dreta
    • Sandra Dotlić
    • Lea Galunić-Bilić
    • Margareta Dobrenić
    • Marko Kralik
    • Pavle Rončević
    • Igor Aurer
  • Show Details

    P017 (187) The role of baseline bulk and dissemination measures as predictors of progression in advanced Hodgkin lymphoma.

    • Michal Taszner
    • Grzegorz Romanowicz
    • Wanda Knopińska-Posłuszny
    • Janusz Hałka
    • Edyta Subocz
    • Bogdan Małkowski
    • Jan Maciej Zaucha
  • Show Details

    P018 (70) Treatment outcomes in classical Hodgkin lymphoma (HL): 5-year update report from the Brazilian Prospective Registry

    • Irene Biasoli
    • Nelson Castro
    • Carolina Colaço Villarim
    • Fabiola Traina
    • Carlos Sergio Chiattone
    • Monica Praxedes
    • Cristiana Solza
    • Leila Perobelli
    • Otavio Baiocchi
    • Rafael Gaiolla
    • Carla Boquimpani
    • Valeria Buccheri
    • Caroline Bonamin Sola
    • Roberta Oliveira de Paula e Silva
    • Ana Carolina Ribas
    • Giovana Steffenello
    • Katia Pagnano
    • Andrea Soares
    • Samuel Souza Medina
    • Talita Silveira
    • Karin Zattar Cecyn
    • Lilian Goveia
    • Leonardo Carvalho Palma
    • Mariana de Oliveira Marques
    • Carmino de Souza
    • Nelson Spector
  • Show Details

    P019 (177) Unfavorable prognostic value of the predominance of THRLBCL-like histopathological growth patterns in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)

    • Elena Dorokhina
    • T.N. Moiseeva
    • A.M. Kovrigina
    • Irirna Shupletsova
    • L.S. Al-Radi
    • Yu. A. Chabaeva
    • Ya.K. Mangasarova

Genomics, Biology & Microenvironment

Selected for Oral Presentation

  • Show Details

    T026 (132) Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma

    • Kristiina Karihtala
    • Suvi-Katri Leivonen
    • Marja-Liisa Karjalainen-Lindsberg
    • Arne Östman
    • Teijo Pellinen
    • Sirpa Leppä
  • Show Details

    T027 (115) High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years

    • Arjan Diepstra
    • Ilja M. Nolte
    • Anke van den Berg
    • Lynn I. Levin
    • Otoniel Martínez-Maza
  • Show Details

    T028 (159) Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade

    • Julia Paczkowska
    • Ming Tang
    • Kyle T. Wright
    • Li Song
    • Vignesh Shanmugam
    • Kelsey Luu
    • Emma L. Welsh
    • Fathima Zumla Cader
    • Elisa Mandato
    • Jing Ouyang
    • Gali Bai
    • Lee Lawton
    • Scott Rodig
    • X Shirley Liu
    • Margaret A. Shipp

Posters

  • Show Details

    P029 (191) Are Reed-Sternberg cells stuck in mitosis by short nucleoplasmic bridges as a consequence of centromeric instability?

    • Radhia M'kacher
    • Steffen Junker
    • Bruno Colicchio
    • Wala Najar
    • Justyna Mika
    • Alain Dieterlen
    • Joanna Polanska
    • Philippe Voisin
    • Eric Jeandidier
    • Patrice Carde
  • Show Details

    P030 (172) Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i

    • Alessandra Romano
    • Claudio Cerchione
    • Gabriella Santuccio
    • Marialudovica Le Moli
    • Annalisa Chiarenza
    • Amalia Figuera
    • Giovanna Motta
    • L. Caruso
    • Sofia Lanza
    • A. Petronaci
    • S. Poidomani
    • Massimo Ippolito
    • Francesco Di Raimondo
  • Show Details

    P031 (101) CD4+ T cells in close proximity to Hodgkin-Reed Sternberg cells are antigen experienced, polyclonal and display an exhausted phenotype

    • Johanna Veldman
    • Jessica Rodrigues Plaça
    • Lauren Chong
    • Martijn Terpstra
    • Mirjam Mastik
    • Léon C. van Kempen
    • Tomohiro Aoki
    • Christian Steidl
    • Anke van den Berg
    • Lydia Visser
    • Arjan Diepstra
  • Show Details

    P032 (139) Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.

    • Tom A. Mulder
    • Maria L. Andersson
    • Lucia Peña-Pérez
    • Kia Heimersson
    • Ioanna Xagoraris
    • Björn E. Wahlin
    • Robert Månsson
    • Lotta Hansson
    • Georgios Z. Rassidakis
    • Marzia Palma
  • Show Details

    P033 (155) Clinical significance of the severity of THRLBCL-like areas in nodular lymphocyte predominant Hodgkin lymphoma

    • Irirna Shupletsova
    • Alla Kovrigina
    • Elena Dorokhina
    • Tatyana Moiseeva
  • Show Details

    P034 (82) Correlation between MTV, TLG and Serum TARC Concentration in Classical Hodgkin Lymphoma during First-Line Treatment

    • Ilaria Romano
    • Benedetta Puccini
    • Elisabetta Abenavoli
    • Leonardo Signori
    • Marianna Palazzo
    • Manuel Ciceri
    • Benedetta Sordi
    • Valentina Berti
    • Michela Zizza
    • Fabiana Pancani
    • Luca Nassi
    • Alessandro Maria Vannucchi
  • Show Details

    P035 (93) CRISPR/Cas9-mediated knockout reveals an important role of CD30 in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma

    • Annika L. Kilian
    • Anna Lollies
    • Marc A. Weniger
    • Ralf Küppers
  • Show Details

    P036 (125) Detection of recurrent somatic variants in cell-free DNA as a tool for disease monitoring in Hodgkin lymphoma

    • Jan Grohmann
    • Alexandra Kredatusova
    • Jana Navratilova
    • Veronika Hanackova
    • Helena Urbankova
    • Vit Prochazka
    • Tomas Papajik
  • Show Details

    P037 (137) High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma

    • Laman Mammadova
    • Jan-Michel Heger
    • Julia Mattlener
    • Sophia Sobesky
    • Melita Cirillo
    • Paul J. Bröckelmann
    • Janine Altmüller
    • Elisabeth Kirst
    • Stefanie Kreissl
    • Mia Lohmann
    • Peter Nürnberg
    • Andreas Engert
    • Peter Borchmann
    • Bastian von Tresckow
    • Sven Borchmann
  • Show Details

    P038 (117) HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma

    • Berit Müller-Meinhard
    • Sarah Reinke
    • Nicole Seifert
    • Andreas Engert
    • Paul J. Bröckelmann
    • Michael Altenbuchinger
    • Wolfram Klapper
  • Show Details

    P039 (102) HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma

    • Johanna Grund
    • Sarah Reinke
    • Annette Plütschow
    • Bastian von Tresckow
    • Peter Borchmann
    • Andreas Engert
    • Paul J. Bröckelmann
    • Wolfram Klapper
  • Show Details

    P040 (173) LINE-1 reverse transcriptase activity in Hodgkin lymphoma cells

    • Annika Wadel
    • Leonie Jaster
    • Martin S. Staege
  • Show Details

    P041 (74) Low percentage of T lymphocytes in Hodgkin's Lymphoma lymph nodes, measured by flow cytometry, is associated with inferior progression free survival regardless of negative interim pet scan status

    • Laura Korin
    • Santiago Cranco
    • Lucia Fuente
    • Adriana Vitriu
    • Paola Ochoa
    • Evelina Babuin
    • Olivia Gelo
    • Luis Ayala
    • Andrea Novoa
    • Paula Tempra
    • Maria Belen Venegas
    • Anahi Vijnovich Baron
    • Norma Tartas
    • Rosario Custidiano
    • Cecilia Foncuberta
    • Julio Sanchez Avalos
  • Show Details

    P042 (185) Metabolic regulation of adaptive response to arginine deprivation in Hodgkin Lymphoma

    • Alessandra Romano
    • Grazia Scandura
    • Gabriella Santuccio
    • Fabrizio Puglisi
    • Daniela Cambria
    • Angela Maria Amorini
    • Enrico La Spina
    • Nunziatina Laura Parrinello
    • Cesarina Giallongo
    • Daniele Tibullo
    • Claudio Cerchione
    • Giovanni Martinelli
    • Giorgia Simonetti
    • Francesco Di Raimondo
  • Show Details

    P043 (110) Molecular pathogenesis of Hodgkin lymphoma

    • Lilian Beeck
    • Markus Schneider
    • Navid Farsijani
    • Bettina Budeus
    • Julia Bein
    • Hendrik Schaefer
    • Sylvia Hartmann
    • Martin-Leo Hansmann
    • Ralf Küppers
  • Show Details

    P044 (161) PIM kinases support protumoral and immunosuppressive phenotype and functions of macrophages in classical Hodgkin Lymphoma

    • Maciej Szydłowski
    • Filip Garbicz
    • Ewa Kurtz
    • Michał Pawlak
    • Patryk Górniak
    • Anna Szumera-Ciećkiewicz
    • Kamil Sokół
    • Monika Kawecka
    • Daria Owczarek
    • Beata Puton
    • Monika Prochorec-Sobieszek
    • Daniela Bellarosa
    • Michał Kurlapski
    • Jan Maciej Zaucha
    • Przemysław Juszczyński
  • Show Details

    P045 (79) Plasma proteome profiling of cardiotoxicity in patients with Hodgkin lymphoma

    • Johan Mattsson Ulfstedt
    • Eva Freyhult
    • Christina Christersson
    • Charlott Mörth
    • Masood Kamali-Moghaddam
    • Anna Eriksson
    • Gunilla Enblad
    • Daniel Molin
  • Show Details

    P046 (138) Preclinical evaluation of novel repurposed drug combinations in Hodgkin lymphoma

    • Mia Lohmann
    • Iris Buchberger
    • Anna Beielstein
    • Başak Kaçar
    • Julia Mattlener
    • Marieke Nill
    • Zhiyuan Shi
    • Jan-Michel Heger
    • Christian Pallasch
    • Roland Ullrich
    • Sven Borchmann
  • Show Details

    P047 (164) Predictive role of the Hodgkin lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group

    • Vit Prochazka
    • Heidi Mocikova
    • Alice Sykorova
    • Jana Markova
    • Marie Lukášová
    • Lubica Gaherova
    • Alexandra Kredatusova
    • Eva Kriegova
    • Maria Maco
    • Tomas Kozak
    • David Belada
    • Tomas Papajik
  • Show Details

    P048 (112) Predictors of risk of relapse in classic Hodgkin lymphoma by flow cytometry

    • Jonathan Fromm
    • Claire Tang
    • Kikkeri N. Naresh
  • Show Details

    P049 (114) Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma

    • Nicole Seifert
    • Sarah Reinke
    • Johanna Grund
    • Berit Müller-Meinhard
    • Andreas Engert
    • Paul J. Bröckelmann
    • Wolfram Klapper
    • Michael Altenbuchinger
  • Show Details

    P050 (168) Reed-Sternberg cells accelerate glycolytic and mitochondrial metabolism of tumor microenvironment cells

    • Michał Kurlapski
    • Maciej Szydłowski
    • Alicja Braczko
    • Marika Frańczak
    • Maciej Zieliński
    • Ryszard Smoleński
    • Przemysław Juszczyński
    • Jan Maciej Zaucha
  • Show Details

    P051 (146) Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers

    • Alexia Piperidou
    • Eleftherios Zografos
    • Theodoros P. Vassilakopoulos
    • Maria K. Angelopoulou
    • Georgios Hlias
    • Vassiliki Pappis
    • George Boutsikas
    • Maria Dimou
    • Kyriaki Petevi
    • Alexandros Kanellopoulos
    • Marie-Christine Kyrtsonis
    • Panayiotis Panayiotidis
  • Show Details

    P052 (78) Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)

    • Ioanna Xagoraris
    • Konstantina Stathopoulou
    • Stefanie Renken
    • Andreas Lundqvist
    • Francois Xavier Claret
    • Elias Drakos
    • Georgios Z. Rassidakis
  • Show Details

    P053 (158) The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)

    • Ioanna Xagoraris
    • Konstantina Stathopoulou
    • Persa Xyderou
    • Marzia Palma
    • Elias Drakos
    • Theodoros P. Vassilakopoulos
    • Georgios Z. Rassidakis
  • Show Details

    P054 (86) The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma

    • Andrea Visentin
    • Edoardo Ruggeri
    • Federica Frezzato
    • Marco Pizzi
    • Alessandro Cellini
    • Francesco Angotzi
    • Chiara Adele Cavarretta
    • Valeria Ruocco
    • Stefano Pravato
    • Filippo Severin
    • Monica Facco
    • Sabrina Manni
    • Francesci Piazza
    • Livio Trentin
  • Show Details

    P055 (111) Validation of the tumor cell-specific rearranged IgG-encoding circulating cell-free DNA for the treatment response monitoring in patients with classic Hodgkin lymphoma

    • Ilia Buhtoiarov
    • Brian Hill
    • Ilan Kirsch
    • Nancy Richter
    • Rabi Hanna
  • Show Details

    P056 (156) Variants of the transcription factor ONECUT2 regulate gene expression in Hodgkin Lymphoma cells

    • Patricia Lein
    • Charles Gwellem Anchang
    • Ines Volkmer
    • Martin S. Staege
  • Show Details

    P115 (77) Distinct signaling pathways and checkpoint molecule expression across histological subtypes of nodular lymphocyte-predominant Hodgkin lymphoma

    • Ilja Kalashnikov
    • Rachel Kositsky
    • Marja-Liisa Karjalainen-Lindsberg
    • Johannes Dunkel
    • Annika Pasanen
    • Cassandra Love
    • Clay Parker
    • Sarah Ondrejka
    • Eric Hsi
    • Ridas Juskevicius
    • Andrew Evans
    • Andrew G. Evans
    • Magdalena Czader
    • Lin Wang
    • Mina Xu
    • Nathan Paulson
    • Mette Ølgod Pedersen
    • Anne Ortved Gang
    • Jean Koff
    • Chad McCall
    • Yaso Natkunam
    • Abner Louissaint
    • Ong Shin Yeu
    • Raju Pillai
    • Jennifer Chapman
    • Catalina Amador
    • Amy Chadburn
    • Rashmi Goswami
    • Amir Behdad
    • Payal Sojitra
    • Eric Tse
    • Naresh Kikkeri
    • Kikkeri

Relapsed/Refractory

Selected for Oral Presentation

  • Show Details

    T098 (163) Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.

    • Anna Sureda-Balari
    • M. José Terol
    • Eva Domingo-Domènech
    • Ana Pilar González Rodriguez
    • Francisca Hernández Mohedo
    • Javier Núñez Céspedes
    • Fátima de la Cruz Vicente
    • Carmen Martínez Muñoz
    • M. Elena Amutio Díaz
    • Raul Córdoba
    • Antonia Rodríguez Izquierdo
    • Samuel Romero Domínguez
    • Javier Briones Meijide
    • Richard Greil
    • Miriam Moreno Velázquez
    • Araceli Rubio
    • Mariana Bastos Oteiro
    • Pilar Gómez
    • Irit Avivi
    • María Casanova
    • Raquel Del Campo García
    • Victor Noriega
    • José Javier Sánchez Blanco
  • Show Details

    T099 (149) High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma

    • Alison J. Moskowitz
    • Gunjan Shah
    • Heiko Schöder
    • Nivetha Ganesan
    • Helen Hancock
    • Theresa Davey
    • Leslie Perez
    • Samia Sohail
    • Alayna Santarosa
    • Charisse Capadona
    • Brittney Munayirji
    • Anita Kumar
    • Oscar Lahoud
    • Connie Batlevi
    • Paul Hamlin
    • David J. Straus
    • Colette Owens
    • Philip Caron
    • Andrew Intlekofer
    • Audrey Hamilton
    • Steven Horwitz
    • Lorenzo Falchi
    • William Johnson
    • Lia Palomba
    • Ariela Noy
    • Matthew Matasar
    • Georgios Pongas
    • Gilles Salles
    • Santosha Vardhana
    • Beatriz Wills Sanin
    • Joachim Yahalom
    • Ahmet Dogan
  • Show Details

    T100 (181) Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)

    • Catherine Diefenbach
    • Opeyemi Jegede
    • Richard Ambinder
    • Jonathon Cohen
    • Michael Robertson
    • Kevin David
    • Ranjana Advani
    • Timothy Fenske
    • Stefan Barta
    • Neil Palmisiano
    • Jakub Svoboda
    • David Morgan
    • Reem Karmali
    • Brad Kahl
    • Stephen M. Ansell

Posters

  • Show Details

    P101 (165) Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin's lymphoma.

    • Ya.K. Mangasarova
    • T.N. Moiseeva
    • L.S. Al-Radi
    • O.V. Margolin
    • L.G. Gorenkova
    • E.S. Nesterova
    • M.O. Bagova
    • E.A. Fastova
    • R.R. Abdurashidova
    • Z.T. Sarakaeva
    • Elena Dorokhina
    • S.K. Kravchenko
    • A.U. Magomedova
    • E.E. Zvonkov
  • Show Details

    P102 (91) Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma

    • Harsh Shah
    • Victoria Vardell
    • Erin Zacholski
    • Amanda Fegley
    • Kalub Fedak
    • Suchitra Sundaram
    • Sridevi Rajeeve
    • Gaurav Goyal
    • Haris Hatic
    • Pallawi Torka
    • Sheeba Ba Aqeel
    • Azra Borogovac
    • Kira MacDougall
    • Shalin Kothari
    • Anna Kress
    • Dipenkumar Modi
    • Elizabeth Travers
    • Nitin Chilakamarri
    • Elizabeth Brem
    • Deborah M. Stephens
    • Boyu Hu
    • Lindsey Fitzgerlad
    • Charlotte Wagner
    • Daniel Ermann
  • Show Details

    P103 (190) Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.

    • Serageldin Kamel
    • Lucia Martiniova
    • Eslam Aboismail
    • Joo Schmidt
    • Sairah Ahmed
    • Ranjit Nair
    • Raphael E. Steiner
    • Michael L. Wang
    • Sarita Soebianto
    • Gregory Ravizzini
    • Tinsu Pan
    • Hun Ju Lee
  • Show Details

    P104 (122) Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.

    • Jozef Michalka
    • Jana Marková
    • Ľubica Gahérová
    • Mária Maco
    • Vít Procházka
    • Jan Kořen
    • Alice Sýkorová
    • Pavla Štěpánková
    • Kateřina Steinerová
    • Lekaa Mohammad
    • Juraj Ďuraš
    • Barbora Velacková
    • Tomáš Doležal
    • Kateřina Benešová
    • Marie Lukášová
    • Andrea Janíková
    • Zdeněk Král
    • Heidi Móciková
  • Show Details

    P105 (145) Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles

    • Chiara Rusconi
    • Francesca Ricci
    • Vittorio R. Zilioli
    • Vincenzo Marasco
    • Eleonora Calabretta
    • Anna Guidetti
    • Cristina Muzi
    • Federico Mazzon
    • Margherita Smania
    • Martina Sollini
    • Erika Meli
    • Marcello Rodari
    • Emanuele Ravano
    • Roberto Cairoli
    • Paolo Corradini
    • Armando Santoro
  • Show Details

    P106 (140) Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience

    • Axel Erenmalm
    • Johan Linderoth
  • Show Details

    P107 (105) Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data

    • Julia Driessen
    • Fer De Wit
    • Alex F. Herrera
    • Pier Luigi Zinzani
    • Ann S. LaCasce
    • Peter D. Cole
    • Craig H. Moskowitz
    • Ramón García Sanz
    • Michael Fuchs
    • Horst Müller
    • Peter Borchmann
    • Armando Santoro
    • Heiko Schöder
    • Josée M. Zijlstra
    • Barbara A. Hutten
    • Alison J. Moskowitz
    • Marie José Kersten
  • Show Details

    P108 (183) Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma

    • Eleonora Calabretta
    • Martina Di Trani
    • Martina Sollini
    • Francesca Ricci
    • Francesco Corrado
    • Vanessa Cristaldi
    • Stefanos Bonovas
    • Fabrizio Marino
    • Rita Mazza
    • Lodovico Terzi di Bergamo
    • Alessio Bruscaggin
    • Maria Cristina Pirosa
    • Stefania Bramanti
    • Arturo Chiti
    • Armando Santoro
    • Davide Rossi
    • Carmelo Carlo-Stella
  • Show Details

    P109 (180) One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma

    • Hannah Moatti
    • Marie-Céleste Laroque
    • Loïc Renaud
    • Odonchimeg Ravdan
    • Charlotte Schmidt-Hieber
    • Isabelle Madelaine
    • Roberta Di Blasi
    • Catherine Thieblemont
    • Pauline Brice
  • Show Details

    P110 (88) Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers

    • Simonetta Viviani
    • Anna Vanazzi
    • Samuele Frassoni
    • Chiara Rusconi
    • Andrea Rossi
    • Alessandra Romano
    • Caterina Patti
    • Corrado Schiavotto
    • Roberto Sorasio
    • Vincenzo Marasco
    • Laura Lissandrini
    • Davide Rapezzi
    • Daniela Gottardi
    • Federica Cocito
    • Antonino Mulè
    • Guido Gini
    • Roberta Zanotti
    • Alessandro Rambaldi
    • Vincenzo Bagnardi
    • Corrado Tarella
  • Show Details

    P111 (143) Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma

    • Swetha Kambhampati
    • Matthew Mei
    • Lu Chen
    • Sandrine Puvurel
    • Robert Chen
    • Leslie Popplewell
    • Liana Nikolaenko
    • Lacolle Peters
    • Saro Armenian
    • Larry Kwak
    • Steven T. Rosen
    • Stephen Forman
    • Alex F. Herrera
  • Show Details

    P112 (162) Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma

    • Matthew Mei
    • Joycelynne Palmer
    • Kami Maddocks
    • Peter Martin
    • Ni-Chun Tsai
    • Eileen Smith
    • Leslie Popplewell
    • Saro Armenian
    • Geoffrey Shouse
    • Robert Chen
    • Larry Kwak
    • Steven T. Rosen
    • Stephen Forman
    • David Bond
    • Alex F. Herrera
  • Show Details

    P113 (154) Promising results with anti-PD-1 therapy in primary refractory Hodgkin lymphoma: a single-centre report

    • Caterina Zerbi
    • Tanja Lazic
    • Roberta Sciarra
    • Caterina Cristinelli
    • Alessandro Mazzacane
    • Federico Carpi
    • Virginia Valeria Ferretti
    • Giulia Gambini
    • Maurizio Bonfichi
    • Luca Arcaini
    • Manuel Gotti
  • Show Details

    P114 (126) Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome

    • Theodoros P. Vassilakopoulos
    • Athanasios Liaskas
    • Giuliana Rizzuto
    • Argyrios Symeonidis
    • Marzia Palma
    • Maria K. Angelopoulou
    • Chara Giatra
    • Flora Kondopidou
    • Maria Dimou
    • Alberto Musseti
    • Ioanna Xagoraris
    • Marina Siakantaris
    • Evgenia Verigou
    • Fotios Panitsas
    • John Asimakopoulos
    • Maria Arapaki
    • Chrysovalantou Chatzidimitriou
    • Marina Belia
    • Sotirios Sachanas
    • Penelope Korkolopoulou
    • Antonello Cabras
    • Eleni Variamis
    • Panayiotis Panayiotidis
    • Maria Bakiri
    • Themistoklis Karmiris
    • Georgios Z. Rassidakis
    • Paolo C